Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm

Abstract

Cancer types are commonly classified by histopathology and more recently through molecular characteristics such as gene expression, mutations, copy number variations, and epigenetic alterations. These molecular characterizations have led to the proposal of prognostic biomarkers for many cancer types. Nevertheless, most of these biomarkers have been proposed for a specific cancer type or even specific subtypes. Although more challenging, it is useful to identify biomarkers that can be applied for multiple types of cancer. Here, we have used a network-based exploration approach to identify a multi-cancer gene expression biomarker highly connected by ESR1, PRKACA, LRP1, JUN and SMAD2 that can be predictive of clinical outcome in 12 types of cancer from The Cancer Genome Atlas (TCGA) repository. The gene signature of this biomarker is highly supported by cancer literature, biological terms, and prognostic power in other cancer types. Additionally, the signature does not seem to be highly associated with specific mutations or copy number alterations. Comparisons with cancer-type specific and other multi-cancer biomarkers in TCGA and other datasets showed that the performance of the proposed multi-cancer biomarker is superior, making the proposed approach and multi-cancer biomarker potentially useful in research and clinical settings.

Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression

“…The SurvExpress bioinformatics resource has previously been applied in research for the external validation of the prognostic value of panels of genes/proteins [29]. It includes data from 8 different prostate cancer datasets containing a total of 1723 samples.…”

Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature

“…For instance, Martinez-Ledesma et al used a network-based clinical association (NCA) algorithm to identify such a multi-cancer biomarker among 12 cancer types that predicts survival outcomes of patients (151).…”

Epithelial Mesenchymal Transition Network-Based Feature Engineering in Lung Adenocarcinoma Prognosis Prediction Using Multiple Omic Data

“…Biological networks, typically protein-protein interaction (PPI) networks, are often used to add constraints in feature selection [22][23][24][25][26][27][28]. For example, in [24] the authors employ a combinatorial approach and find groups of genes that are connected in the PPI network and whose expression status together can differentiate patient survival time in glioblastoma multiforme (GBM) cancer.…”